COMMUNIQUÉS West-GlobeNewswire
-
Trinity Biotech Launches Trinovium to Bring Healthcare-Grade Fluid Technology to the Rapidly Growing Multi-Billion Dollar AI Data Center Liquid Cooling Market
23/06/2026 -
UREVO Mid-Year Sale Brings 2026's Biggest Deal Yet to Amazon and Official Website
23/06/2026 -
Cytonus Therapeutics Becomes Axiom Biosciences, Pairing Its Regenerative Medicine Programs With AI-Enabled Drug Design
23/06/2026 -
Oryn Therapeutics Advances Next Phase of Orynotide™ Macrocyclic Peptide Platform Development with Expanded Leadership Team and Board Anchored by Accomplished Life Sciences Industry Veterans, Company Builders and Drug Developers
23/06/2026 -
Soleo Health Named URAC Performance Measurement Pioneer for Second Consecutive Year
23/06/2026 -
Avalo Therapeutics Appoints Ron Philip to Board of Directors
23/06/2026 -
Advanced Rehabilitation, LLC Expands iKNOT Curriculum to Address Complex Regional Pain Syndrome & Chronic Upper Extremity Problems
23/06/2026 -
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
23/06/2026 -
Transactions in connection with share buy-back program
23/06/2026 -
CGA.vitaslim Announces Mission to Help 5,000 Adults Combat the "Three Highs" and Reclaim Their Health and Wealth in Hong Kong
23/06/2026 -
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission
23/06/2026 -
BienRaíz Launches Vitamin D3 5000 IU Softgels: A High-Potency, Simple Formula for Everyday Wellness
23/06/2026 -
Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
23/06/2026 -
Nicox et Vester Finance signent une convention d’avance en compte courant d’actionnaire en support des activités stratégiques de la Société
23/06/2026 -
Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
23/06/2026 -
Communiqué de presse : Wayrilz de Sanofi a été approuvé au Japon pour traiter la thrombocytopénie immunitaire
23/06/2026 -
argenx to Host Autoimmune Myositis R&D Webinar
23/06/2026 -
Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
23/06/2026 -
Communiqué de presse : Cenrifki (tolebrutinib) de Sanofi approuvé dans l’UE comme premier médicament ciblant la progression du handicap dans la sclérose en plaques secondairement progressive sans rechutes
23/06/2026
Pages